To determine whether mice with priming defects due to impaired cross-presentation still required late stage type I IFN for CD8+ T cell maturation, MAR1-5A3 or control GIR-208 MAb was administered to wild type or BATF3-/- mice at day 4 after WNV-NY infection. The gene discussed is BATF3; the disease is infection.